Thermal Ablation Combined with Immune Checkpoint Blockers: A 10-Year Monocentric Experience.

ABSTRACT:

Purpose

We report a 10-year experience in cancer therapy with concomitant treatment of percutaneous thermal ablation (PTA) and immune checkpoint blockers (ICBs).

Material and methods

This retrospective cohort study included all patients at a single tertiary cancer center who had received ICBs at most 90 days before, or 30 days after, PTA. Feasibility and safety were assessed as the primary outcomes. The procedure-related complications and immune-related adverse events (irAEs) were categorized according to the Common Terminology Criteria for Adverse Events v5.0 (CTCAE). Efficacy was evaluated based on overall survival (OS), progression-free survival (PFS), and local progression-free survival (_LPFS) according to the indication, ablation modality, neoplasm histology,

SUBMITTER: Bonnet B 

PROVIDER: S-EPMC10931410 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature